Organon Operating Margin from 2010 to 2026

OGN Stock  USD 7.91  0.30  3.65%   
Organon Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to grow to 0.35 this year.
Check Organon financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organon's main balance sheet or income statement drivers, such as Depreciation And Amortization of 236.8 M, Interest Expense of 627.9 M or Selling General Administrative of 1.2 B, as well as many indicators such as Price To Sales Ratio of 1.05, Dividend Yield of 0.0434 or PTB Ratio of 9.81. Organon financial statements analysis is a perfect complement when working with Organon Valuation or Volatility modules.
  
Build AI portfolio with Organon Stock
Check out the analysis of Organon Correlation against competitors.
Evaluating Organon's Operating Margin across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Organon Co's fundamental strength.

Latest Organon's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Organon Co over the last few years. It is Organon's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Organon's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.23 %10 Years Trend
Pretty Stable
   Operating Profit Margin   
       Timeline  

Organon Operating Margin Regression Statistics

Arithmetic Mean0.31
Geometric Mean0.31
Coefficient Of Variation21.16
Mean Deviation0.04
Median0.31
Standard Deviation0.07
Sample Variance0
Range0.2828
R-Value(0.13)
Mean Square Error0
R-Squared0.02
Significance0.62
Slope(0)
Total Sum of Squares0.07

Organon Operating Margin History

2026 0.35
2025 0.27
2024 0.23
2023 0.21
2021 0.3
2020 0.44
2019 0.49

About Organon Financial Statements

Organon investors utilize fundamental indicators, such as Operating Margin, to predict how Organon Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Organon Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Organon Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon CO operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 9300 people.

Pair Trading with Organon

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organon will appreciate offsetting losses from the drop in the long position's value.

Moving together with Organon Stock

  0.62JNJ Johnson JohnsonPairCorr
  0.82LPCN LipocinePairCorr

Moving against Organon Stock

  0.81HPQ HP IncPairCorr
  0.54BRK-A Berkshire HathawayPairCorr
  0.5MSFT MicrosoftPairCorr
  0.32IBM International BusinessPairCorr
The ability to find closely correlated positions to Organon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organon Co to buy it.
The correlation of Organon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organon moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Organon offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organon Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organon Co Stock:
Check out the analysis of Organon Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Pharmaceuticals sector continue expanding? Could Organon diversify its offerings? Factors like these will boost the valuation of Organon. Anticipated expansion of Organon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organon data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.56)
Dividend Share
0.6
Earnings Share
1.91
Revenue Per Share
24.34
Quarterly Revenue Growth
0.013
Investors evaluate Organon using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organon's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organon's market price to deviate significantly from intrinsic value.
It's important to distinguish between Organon's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organon should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organon's market price signifies the transaction level at which participants voluntarily complete trades.